الفهرس | Only 14 pages are availabe for public view |
Abstract The progressive hepatic fibrosis with the development of cirrhosis is a feature of almost all chronic liver diseases. Approximately 10–20% of patients with chronic hepatitis C virus infection have cirrhosis at first clinical presentation, and as many 20–30% of those who do not have cirrhosis will eventually develop this condition and its complications with in one or more decades These complications are liver failure, ascites, variceal bleeding, portal-systemic encephalopathy, and hepatocellular carcinoma. (Foucher et al., 2005). Until recently, liver biopsy (LB) examination was the only way of evaluating liver fibrosis. However, LB examination is invasive and painful, and can have life-threatening complications. The poor acceptability of LB examination can lead to treatment delays, and LB examination is difficult to repeat in poorly symptomatic subjects. The accuracy of LB examination for assessing fibrosis also has been questioned because of sampling errors and intra- and inter-observer variability that may lead to over- or under staging of fibrosis. There is thus a need for accurate noninvasive methods of measuring the degree of liver fibrosis. Proposed approaches include physical examination, routine biochemical and hematologic tests, surrogate serum fibrosis markers have been used (Castera, 2005). The Fibroscan is a simple and low-cost device that could be used to assess instantaneously and directly the elasticity of the liver. The measurements are fully non-invasive, and may be performed by physicians or even non physicians after a short training period, there is no intra-or interobserver variability and the technique is reproducible (Sandrin et al., 2005). Correlation with fibrosis grade is good with good sensitivity and specificity values and high positive predictive values(in comparison to liver biopsy) especially in moderate and sever stages of fibrosis ≥ f2 (reaches more than 90%) (Foucher et al., 2006). Because the Transient Elastography completely noninvasive and because stiffness is a continuous variable, repeated measurements could show changes in the amount of fibrosis and help follow-up in these patients (Ziol et al., 2005). Also elasticity measurements have good correlation with complication of fibrosis as cirrhosis, oesophageal varices and hepatocellular carcinoma (Foucher J et al., 2006).Transient elastography could be useful not only to evaluate liver fibrosis as to monitor liver disease progression, but also to monitor anti-viral or antifibrotic therapy effects and to help taking decisions in daily clinical practice (Gomez et al., 2006). Several studies evaluated the accuracy of Fibroscan, blood tests, or combinations compared with liver biopsy (Shiha et al., 2009). Most of these studies include patients with HCV infection, one includes patients with chronic liver disease of any origin, one includes patients with biliary cirrhosis due to primary biliary cirrhosis or primary sclerosing cholangitis, and one includes only those patients who are co infected with HIV and HCV. These studies show that Fibroscan results are reproducible across operators and time. All the studies report that FibroScan‟s diagnostic performance is good, indicating that it agrees perfectly with liver biopsy. (Shiha et al., 2009) Elasticity measurements are difficult or impossible in obese patients and patients with narrow intercostal spaces, also fat tissue may absorb or diminish low-frequent vibration, resulting in a poor signal to noise ratio that affects the elasticity measurement algorithm in this patient. The lowfrequency elastic waves do not propagate Through liquids, indicating that elastometry is impossible in patients with ascites. The chest wall contributes to prevent the liver from being directly compressed by the probe itself, and to give a static and plane surface for the probe positioning. Blood flow might be another consistent factor for the measurement It self (Saito et al., 2003). But this last limitation is to be overcome by technical improvements such as the development of new probes. Our study showed that the relation between fibroscan and US finding had positive correlation as most of patients with hepatomegaly, coarse hepatic texture, dilated PV or splenomegaly reported as high fibrosis (F3 and F4 scores) while sporadic cases were reported in (F0, F1 and F2 scores). Also in our study there was highly statistically significant agreement between degrees of fibrosis by biopsy and degrees of fibrosis by fibro-scan , that means that Fibroscan is a good tool in detection of hepatic fibrosis and follow up of it. |